Research Article
The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations
Table 6
Means and medians of survival analysis times.
| | Take your medication | Average valueb | Median | | Estimate | Standard error | 95% confidence interval | Estimate | Standard error | 95% confidence interval | | Lower limit | Upper limit | Lower limit | Upper limit |
| | Exon 19 deletion | 58.283 | 3.342 | 51.733 | 64.833 | — | — | — | — | | Exon 20 T790M | 42.936 | 4.366 | 34.378 | 51.494 | 44.500 | 6.578 | 31.607 | 57.393 | | Exon 21 L858 | 62.367 | 1.660 | 59.113 | 65.621 | — | — | — | — | | Overall | 51.140 | 2.898 | 45.461 | 56.820 | 53.600 | — | — | — |
|
|
aEGFR mutation = positive. bIf the survival analysis time has been checked, then the estimate will be limited to the maximum survival analysis time.
|
